Close Menu

aneuploidy

NEW YORK (GenomeWeb News) – Illumina said after the close of the market Thursday that it has completed its $450 million acquisition of Verinata Health.

Quest Diagnostics has agreed to distribute Panorama, Natera's noninvasive targeted SNP sequencing-based test to diagnose fetal aneuploidies, following Natera's announcement of the commercial launch of the test this week.

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has signed an agreement to offer a non-invasive prenatal test developed by Natera.

NEW YORK (GenomeWeb News) – Singapore-based women's health diagnostic firm Inex Innovations Exchange on Monday announced an exclusive deal with Primary Health Care for the distribution of Inex's non-invasive fetal chromosomal abnormality test in Australia.

NEW YORK (GenomeWeb News) – NewBridge Pharmaceuticals today announced an agreement to offer Verinata Health's non-invasive prenatal tests in the Middle East and surrounding areas.

NEW YORK (GenomeWeb News) – Aetna this week issued a clinical policy bulletin suggesting that it may soon begin covering non-invasive prenatal DNA tests for Down syndrome.

NEW YORK (GenomeWeb News) – Start-up KellBenX is positioning itself as the David among the Goliaths of the non-invasive prenatal diagnostics space by building a test that it said can detect fetal chromosomal abnormalities beyond aneuploidies.

Following last week's announcement that Illumina had acquired Verinata Health in a deal worth up to $450 million, other companies that use Illumina's technology for their own noninvasive prenatal tests said the acquisition, though unexpected, ultimately validates the field.

Since Sequenom launched the first noninvasive prenatal sequencing test for Down syndrome and other fetal aneuploidies in October 2011, the field has exploded.

This article has been updated from a previous version to clarify the company's reimbursement goals for 2013.

Pages

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.